Roche announced on Tuesday, October 27, 2026, that it has received the CE Mark for its cobas smart e immunoanalyser, a compact benchtop platform designed to bring central-laboratory testing into smaller hospitals, clinics and decentralised laboratories. The announcement, made from Basel, Switzerland, completes a portfolio that Roche says now spans settings from small clinics to the highest-volume hospital laboratories.
The point is not a bigger machine, but a smaller one that can sit where the patients already are. For smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests, sending samples away and waiting for results to come back. Roche says the new system is engineered to change that equation, fitting central-laboratory precision into a footprint under one square metre, at about 0.9 square metres, so testing can be done in-house instead.
Key Takeaways
- Roche received the CE Mark on October 27, 2026, for the cobas smart e immunoanalyser, a compact benchtop system for smaller laboratories.
- The system offers a planned menu of over 100 high-medical-value assays, with reaction times of 18 minutes or less for more than 90% of Roche immunoassays.
- It uses the same reagents and Elecsys technology as Roche’s high-throughput central-laboratory platforms, so results stay comparable across sites.
What the System Is Designed to Do
The cobas smart e is the newest addition to Roche’s cobas immunoassay systems portfolio. It holds 36 reagent positions on its compact benchtop footprint and, according to Roche, offers up to two hours of walk-away time on a load of 36 samples. Its planned menu covers more than 100 assays across critical disease areas, including cardiometabolic, oncology and infectious diseases, with assays to be launched in sequential waves.
That breadth matters for a low-volume laboratory. A small site cannot justify a separate platform for every kind of test, and it cannot afford to send every sample to a distant central laboratory if the answer is needed the same day. By bringing essential testing in-house, Roche says, the system can reduce both the delay and the cost of sending samples out, while keeping results consistent with those produced on larger platforms.
The point is not a bigger machine, but a smaller one that can sit where the patients already are.
Why Smaller Labs Struggle Today
Across global healthcare systems, workforce shortages continue to strain diagnostic delivery. Roche cites a projected global shortfall of 11 million health workers by 2030, a figure drawn from World Health Organization workforce data. In that context, a platform that demands constant attention from scarce specialists is a poor fit for a small clinic, however accurate it may be.
The cobas smart e is designed around that constraint. Roche says it combines minimal maintenance with guided, step-by-step tasks to simplify workflows and improve the productivity of laboratory personnel. It requires just one single minute of daily operator intervention, reducing hands-on maintenance efforts by up to two-thirds compared with previous-generation platforms, according to Roche’s pre-launch data. Lab automation is part of a wider shift toward tools that handle routine work with less hands-on time, and the same pressure to do more with fewer hands is visible across healthcare and beyond.
Physical conditions matter too. Roche says the platform is engineered to withstand challenging conditions that often limit testing in decentralised settings, with an integrated water tank, standard power compatibility and a dust-protection design. That utility-independent engineering, the company says, bypasses traditional infrastructural barriers and enables uninterrupted service across rural and resource-constrained clinics.
- Footprint of about 0.9 square metres, fitting on a laboratory benchtop
- 36 reagent positions and up to two hours of walk-away time on a 36-sample load
- Reaction times of 18 minutes or less for more than 90% of Roche immunoassays
- One minute of daily operator intervention, according to Roche
- Same universal reagents and Elecsys technology as Roche’s central-laboratory platforms
- Planned menu of over 100 assays across cardiometabolic, oncology and infectious diseases
How It Fits the Wider Roche Portfolio
The cobas smart e joins the cobas e 402 and cobas e 801 analytical units, which run up to 60, 120 and 300 tests an hour respectively. Together, Roche says, the three systems scale from small local clinics to the highest-volume hospital laboratories, using the same universal reagents and Elecsys technology. That shared technology is the key to comparability: a result produced in a small clinic should be comparable with a result produced in a central laboratory, and a patient whose care moves between sites should not face a different standard of testing at each stop.
Matt Sause, chief executive of Roche Diagnostics, framed the launch in those terms. He said that for smaller hospitals and laboratories, maintaining central-lab quality has traditionally meant outsourcing tests, and that the new benchtop system brings Roche’s immunoassay standards directly into those care settings. The result, he said, is that the company’s immunoassay solutions now span the full range of healthcare settings, with consistent, high-quality results intended to give patients timely, accurate answers no matter where they live.
For more detail, Roche is presenting the system at the International Federation of Clinical Chemistry and Laboratory Medicine conference in New Delhi, India, from October 25 to 29, 2026.
What to Watch Next
What to watch next is only what this announcement already sets out: whether smaller laboratories adopt a benchtop system that promises central-lab precision in under one square metre, whether the planned menu of over 100 assays arrives in its sequential waves as described, and whether results from decentralised sites prove as comparable with central-laboratory results as Roche says they will be. The other test is whether the guided workflows and minimal daily intervention ease the staffing pressure on small laboratories, and whether the system performs as described in rural and resource-constrained clinics. Until those questions are answered in routine use, the CE Mark stands as the milestone Roche announced on October 27: a compact analyser cleared for its intended market, aimed at the clinics that have so far had to send their testing away.